• Explore /
  • Poster
  • / FIDES-02, a phase Ib/II study of derazantinib (DZB) as monotherapy and combination therapy with atezolizumab (A) in patients with surgically unresectable or metastaticurothelial cancer (UC) and FGFR genetic aberrations.

FIDES-02, a phase Ib/II study of derazantinib (DZB) as monotherapy and combination therapy with atezolizumab (A) in patients with surgically unresectable or metastaticurothelial cancer (UC) and FGFR genetic aberrations.

Abstract Poster

Authors

null

Arvind Chaudhry

Med Onc Assoc P S, Spokane, WA

Arvind Chaudhry , Cora N. Sternberg , Maria De Santis , Joaquim Bellmunt , Andrea Necchi , Thomas Powles , Frederique Cantero , Michalina Marszewska , Michal Grzyb , Paul McSheehy , Stephan Braun , Arlene O. Siefker-Radtke

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers

Track

Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04045613

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr TPS590)

Abstract #

TPS590

Poster Bd #

N8

Abstract Disclosures

Similar Posters

First Author: Charles S. Fuchs

First Author: Natalie Rainey

First Author: Samuel Aaron Funt

First Author: Roberto Iacovelli